Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Atezolizumab in combination with Carboplatin and Nab-paclitaxel in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.